CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
通过合成生物学增强嵌合抗原受体 NK 细胞的生理特性
英文原题：Enhancing the physiological characteristics of chimeric antigen receptor natural killer cells by synthetic biology.
查看英文原题
Enhancing the physiological characteristics of chimeric antigen receptor natural killer cells by synthetic biology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体自然杀伤（CAR-NK）细胞疗法代表了继CAR-T 细胞疗法之后的下一代免疫治疗策略，具有固有的“现货型”兼容性和较低的脱靶毒性。尽管具备这些优势，其临床转化仍受限于体内持久性差以及在免疫抑制性肿瘤微环境（TME）中的功能耗竭。本综述探讨了合成生物学在增强CAR-NK细胞生理特性方面的最新进展。通过阐述NK细胞与合成生物学工具包之间的协同作用，本工作为开发能够应对实体瘤挑战同时保持良好安全性的下一代CAR-NK疗法提供了路线图。
展开英文摘要原文
Chimeric antigen receptor natural Killer (CAR-NK) cells therapy represents a next-generation immunotherapeutic approach following CAR-T cells therapy, offering inherent "off-the-shelf" compatibility and mitigated off-tumor toxicity. Despite these advantages, clinical translation remains constrained by poor in vivo persistence and functional exhaustion in immunosuppressive tumor microenvironments (TME).
This review examines recent advancements in synthetic biology aimed at enhancing the physiological characteristics of CAR-NK cells. By delineating the synergy between NK cells and synthetic biology toolkits, this work provides a roadmap for developing next-generation CAR-NK therapies capable of addressing solid tumor challenges while maintaining favorable safety profiles.
论文信息
- 作者
- Ji S、Jin C、Cui X
- 单位
- Affiliated Hospital of Shandong Second Medical University, Weifang, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40313937 · DOI 10.3389/fimmu.2025.1592121
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →